18F-FDG-PET Imaging for Post-COVID-19 Brain and Skeletal Muscle Alterations.
Thorsten RudroffCraig D WorkmanLaura L Boles PontoPublished in: Viruses (2021)
Scientific evidence concerning the subacute and long-term effects of coronavirus disease 2019 (COVID-19) is on the rise. It has been established that infection by serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a systemic process that involves multiple organs. The complications and long-term consequences of COVID-19 are diverse and patients need a multidisciplinary treatment approach in the acute and post-acute stages of the disease. A significant proportion of COVID-19 patients experience neurological manifestations, some enduring for several months post-recovery. However, brain and skeletal muscle changes resultant from SARS CoV-2 infection remain largely unknown. Here, we provide a brief overview of the current knowledge, and usefulness, of [18F]fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) to investigate brain and skeletal muscles changes in Post-COVID-19 patients with persistent symptoms. Furthermore, a brief discussion of future 18F-FDG-PET/CT applications that might advance the current knowledge of the pathogenesis of post-COVID-19 is also provided.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- positron emission tomography
- computed tomography
- pet imaging
- skeletal muscle
- liver failure
- pet ct
- respiratory failure
- drug induced
- white matter
- resting state
- aortic dissection
- magnetic resonance imaging
- cerebral ischemia
- ejection fraction
- end stage renal disease
- insulin resistance
- acute respiratory distress syndrome
- type diabetes
- dual energy
- chronic kidney disease
- hepatitis b virus
- functional connectivity
- adipose tissue
- risk factors
- depressive symptoms
- patient reported